News

This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. Ipsen chief commercial officer and

Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. Treatment with LYRICA at

Aimovig blocks the calcitonin gene-related peptide receptor (CGRP-R), which is considered to play an important role in migraine. The drug’s effectiveness for the preventive treatment of migraine was

The agreement is a strategic step with the leading contract manufacturer in India to extend the opportunities offered by LPLDL into India and Southern Asia. Under the terms

This phase 2a multi-centre and multi-country clinical trial (CDKO-125A-010) in sorafenib-refractory or -intolerable patients with unresectable or metastatic hepatocellular carcinoma (HCC) is being conducted in Greece, Italy and

The regulator issued a complete response letter to Evolus citing deficiencies related to chemistry, manufacturing and controls processes. Evolus noted that the FDA did not identify any deficiencies

The series B financing round was headed by Sequoia China and LYFE Capital, and supported by existing series A investors such as VI Ventures and Nest.Bio Ventures and

Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments,

In the merger, each share of AveXis common stock outstanding immediately prior to the effective time of the merger (other than shares owned by Novartis, Merger Sub, AveXis